Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31092820 | 1.00 | ACE (0.55) | ACE | |
| SCHEMBL29545684 | 1.00 | ACE (0.55) | ACE | |
| SCHEMBL29443087 | 1.00 | ACE (0.55) | ACE | |
| SCHEMBL3702462 | 1.00 | ACE (0.55) | ACE | |
| SCHEMBL927332 | 1.00 | ACE (0.55) | ACE | |
| SCHEMBL7950933 | 0.95 | ACE (0.51) | ACE | |
| SCHEMBL7950930 | 0.95 | ACE (0.51) | ACE | |
| SCHEMBL17031897 | 0.89 | NOTUM (0.44) | ACE | |
| SCHEMBL17032680 | 0.89 | NOTUM (0.50) | ACE | |
| SCHEMBL6582273 | 0.88 | OPRL1 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 322 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6258815-B1 | HETEROCYCLIC COMPOUNDS | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 2001-07-10 | — | — | US | claimed |
| US-12606817-B2 | Methods of creating and screening DNA-encoded libraries | X-CHEM, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-12338230-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS AG (CH) | 2025-05-29 | — | — | US | disclosed |
| US-20250163030-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12297205-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| EP-3589628-B1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2025-05-07 | — | — | EP | disclosed |
| EP-3985002-B1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2025-05-07 | — | — | EP | disclosed |
| EP-4129407-B1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2024-12-25 | — | — | EP | disclosed |
| US-12162860-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-RE37094-E1 | Heterocyclic substituted acylaminothiazoles, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 2001-03-13 | — | — | US | disclosed |
| US-6100238-A | USEFUL AS INHIBITORS OF HUMAN NEUTROPHIL ELASTASE (HNE) FOR THE TREATMENT OF HNE-MEDIATED PROCESSES IMPLICATED IN CONDITIONS SUCH AS ADULT RESPIRATORY DISTRESS SYNDROME, SEPTIC SHOCK AND MULTIPLE ORGAN FAILURE | CORTECH INC. (US) | 2000-08-08 | — | — | US | disclosed |
| WO-1999062514-A1 | INDOLE AND TETRAHYDROISOQUINOLINE CONTAINING α-KETO OXADIAZOLES AS SERINE PROTEASE INHIBITORS | CORTECH INC. (US) | 1999-12-09 | — | — | WO | disclosed |
| US-5965556-A | KETO-ACID AMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS FOR INHIBITING THE ACTIVITY OF SERINE PROTEASE OR THIOL PROTEASE BY ADMINISTERING THE DERIVATIVE TO A MAMMAL; ALZHEIMER'S DISEASE | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYUKAI (JP) | 1999-10-12 | — | — | US | disclosed |
| US-5756763-A | ENZYME INHIBITOR | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYUKAI (JP) | 1998-05-26 | — | — | US | disclosed |
| EP-0709373-A1 | NOVEL PYRROLIDINE DERIVATIVE | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1996-05-01 | — | — | EP | disclosed |
| US-5340801-A | Compounds having cholecystokinin and gastrin antagonistic properties | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1994-08-23 | — | — | US | disclosed |
| WO-1993020099-A2 | CCK AND/OR GASTRIN RECEPTOR LIGANDS | FERRING B.V. (NL) | 1993-10-14 | — | — | WO | disclosed |
| US-5189049-A | Cholecystokinin and gastrin inhibitors | SANOFI (FR) | 1993-02-23 | — | — | US | disclosed |
| US-5047400-A | Treatment of infection; antitumor agents | ADIR ET CIE (FR) | 1991-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12338230-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders | CFD, TFPI, CFH | ACE 212/4885 |
| US-20250163030-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | PIR, CYP3A43, CYP1A2 | ACE 299/4885 |
| US-12606817-B2 | Methods of creating and screening DNA-encoded libraries | PCNA, DNA2, POLM | ACE 2950/4885 |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | PSMA1, CSNK1G1, CSNK1A1 | ACE 2025/4885 |
| US-12162860-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | ACE 167/4885 |
| US-12297205-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | ACE 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.